Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McKay, John
NCT06523621: Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel	Recruiting	2	50	US	Nivolumab, Opdivo	Wake Forest University Health Sciences, Atrium Health Levine Cancer Institute, Bristol-Myers Squibb	Multiple Myeloma	11/27	11/27
NCT04009109: Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM	Active, not recruiting	2	79	US	Lenalidomide, Revlimid, Ixazomib, Ninlaro, Daratumumab Injection, Darzalex, Dexamethasone, Ozurdex	Alliance Foundation Trials, LLC., Janssen Scientific Affairs, LLC, Celgene Corporation, Takeda	Myeloma, Multiple	10/25	07/26
NCT05911321: Isa-Pom-Dex in Elderly/Frail Subjects With RRMM	Active, not recruiting	2	6	US	Isatuximab, Pomalidomide, Dexamethasone	UNC Lineberger Comprehensive Cancer Center, Genzyme, a Sanofi Company	Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity	06/25	03/28
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma	Completed	1/2	272	Europe, Canada, Japan, US, RoW	Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone	Takeda, Takeda Development Center Americas, Inc.	Multiple Myeloma	07/24	11/24
NCT04822337: Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma	Recruiting	1/2	70	US	Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin	Wake Forest University Health Sciences, Amgen, GlaxoSmithKline	Multiple Myeloma	04/29	11/32

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McKay, John
NCT06523621: Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel	Recruiting	2	50	US	Nivolumab, Opdivo	Wake Forest University Health Sciences, Atrium Health Levine Cancer Institute, Bristol-Myers Squibb	Multiple Myeloma	11/27	11/27
NCT04009109: Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM	Active, not recruiting	2	79	US	Lenalidomide, Revlimid, Ixazomib, Ninlaro, Daratumumab Injection, Darzalex, Dexamethasone, Ozurdex	Alliance Foundation Trials, LLC., Janssen Scientific Affairs, LLC, Celgene Corporation, Takeda	Myeloma, Multiple	10/25	07/26
NCT05911321: Isa-Pom-Dex in Elderly/Frail Subjects With RRMM	Active, not recruiting	2	6	US	Isatuximab, Pomalidomide, Dexamethasone	UNC Lineberger Comprehensive Cancer Center, Genzyme, a Sanofi Company	Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity	06/25	03/28
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma	Completed	1/2	272	Europe, Canada, Japan, US, RoW	Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone	Takeda, Takeda Development Center Americas, Inc.	Multiple Myeloma	07/24	11/24
NCT04822337: Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma	Recruiting	1/2	70	US	Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin	Wake Forest University Health Sciences, Amgen, GlaxoSmithKline	Multiple Myeloma	04/29	11/32